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Introduction 
Maraviroc, a recently marketed Pfizer drug for HIV treatment, is an excellent representation 
of a drug developed employing a fail fast fail cheap strategy whereby its target (CCR5) 
affinity was improved whilst reducing unwanted side effects.1 It is pointless and 
uneconomical (and easily said in hindsight!) to spend hundreds of millions of pounds in 
developing a drug only to see that it fails clinical trials due to a side effect that could have 
been eliminated or “red lighted” during the (cheaper) drug discovery stage. In this article, we 
will present a case study on the development of maraviroc (Fig. 20.38, Patrick 4th Ed), the 
elimination of unwanted off-target HERG affinity2 (see Box 12.3, Patrick 4th Ed) and 
currently developed second generation molecules. An initial introduction to familiarise the 
reader with the CCR5 receptor and the importance of eliminating HERG in drug development 
will be presented. 
 
The CCR5 Receptor is a GPCR (Chapter 5, Patrick 4th Ed), which is actively involved in the 
HIV cycle (Chapter 20, p 484, Patrick 4th Ed) acting as a co-receptor to the CD4 receptor and 
gp120 on the cell surface before viral entry. CCR5 antagonists have been actively sought to 
combat HIV infection.  
 
HERG ion channel, the human ether-a-go-go related gene!!! (K+ channel) is associated with 
long QT Syndrome, torsades de pointes, arrhythmia and sudden cardiac death. A number of 
drugs have been withdrawn from the market due to HERG problems, including terfenadine, 
an antihistamine. Curiously, terfenadine is not an active H1 receptor antagonist; it is a 
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prodrug of fexofenadine via metabolism by CYP3A4. Contraindications include grapefruit 
juice or other medications which are known to inhibit the metabolic cytochrome 
P450enzyme, CYP3A4. The high levels of terfenadine that result from blocked metabolism 
can lead to cardiotoxicity, due to the ability of terfenadine to block the HERG ion channel in 
cardiac muscle. As a result, terfenadine was withdrawn from the market and replaced by 
fexofenadine (its active metabolite). 
 
 
Metabolism of terfenadine (left) to fexofenadine (right). 
 
Cisapride and dofetilide are further examples of agents that suffer serious side effects as a 
result of blocking the HERG channel. The former has since been withdrawn from the market 
as a prokinetic agent (5HT4 agonist) and the latter is only used under strict medical 
supervision for treating atrial fibrillation. Isotopically labelled (3H) dofetilide is used as a 
displaceable ligand in high throughput binding assays for HERG activity. 
 
Therefore, given the unwanted cardiotoxicity associated with HERG channel blockage, 
factoring out HERG activity in molecules during the drug discovery process is an important 
approach employed by many pharmaceutical companies.  
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Development of maraviroc 
In the search for a small molecule CCR5 antagonist, scientists at Pfizer started with the rather 
complicated lead molecule 1, consisting (from left to right) of a cyclobutane carboxamide 
linked via an alkyl spacer to tropane and benzimidazole rings. However, 1 displayed high 
affinity towards the HERG channel and so analogues were synthesised with the aim of 
eliminating  such undesirable affinity whilst improving CCR5 affinity.3  
 
Several approaches were employed, to look at the SAR (structure activity relationship) by 
modifying: 
i) the basicity of the central (tropane) nitrogen 
ii) the substitution pattern of the aromatic ring of the benzimidazole 
iii) the lipophilicity of the molecule 
iv) the basicity of the cyclobutyl carboxamide group 
 
Approach i)  
One reason for modifying the tropane ring system was to investigate whether the basicity of 
the tropane nitrogen played a role in affinity towards the CCR5 receptor or HERG ion 
channel. One analogue which was synthesised was structure 2, containing an oxygen 
bridgehead. Although the basicity of the central nitrogen was significantly reduced (pKa=7.8 
for 1 vs. 6.0 for 2), the affinity of both compounds towards HERG was similar, suggesting 
that the basicity of the central nitrogen atom has little effect on HERG affinity. 
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Approaches ii) and iii) 
Removal of the fused aromatic ring in 1, as in the synthesis of 3 and 4, led to very good 
antiviral activity and low HERG affinity. The drop in HERG affinity could be rationalised 
from molecular modelling experiments where structure 1 was docked into the binding site of 
a HERG model. These suggested that there was a good overlay of the aromatic ring of the 
benzimidazole ring in structure 1 with a lipophilic region of the HERG channel. Therefore, 
removing the aromatic ring removed this interaction and lowered affinity. 
 
Approach iv) 
Structure 4 was now established as the new lead compound. The molecular modelling 
experiments described above had also shown that there was a favourable hydrophobic 
interaction between the cyclobutyl carboxamide group of structure 1 and the HERG channel. 
Therefore, the next tactic was to disrupt this interaction. Changing the ring size in 4 from a 
four membered cyclobutane unit to a cyclopentane unit (structure 5), termed a homologation, 
led to a significant increase in antiviral potency and loss of HERG affinity. The loss of 
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HERG affinity was due presumably to the larger cyclopentyl ring having unfavourable steric 
interactions with the binding site of the HERG ion channel.  In contrast, the fluorinated 
analogue 6 had both reduced antiviral potency and HERG affinity.  
 
Further modification of 6 led, eventually, to maraviroc 7, containing a gem-
difluorocyclohexyl group. Maraviroc retained excellent antiviral activity at the nanomolar 
level, whilst exhibiting no significant HERG binding affinity. The lack of HERG binding 
affinity was due to the large size of the cyclohexyl group and the high polarity of the fluoro 
substituents. Both factors disfavoured binding to a lipophilic region of the HERG channel, a 
result that had been predicted through molecular modelling. 
 
The next generation of CCR5 antagonists are now being developed, including the maraviroc-
like 8.4,5 The aims are to improve biological properties, and to overcome probable drug 
resistance where the virus may make use of the CXCR4 receptor for viral entry rather than 
the (antagonised/blocked) CCR5 receptor. 
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Vicriviroc 12, like maraviroc, is a CCR5 antagonist. It acts as an allosteric modulator, 
creating a conformational change in CCR5, preventing binding of gp120 to the target cell, 
thus thwarting HIV viral entry into the cell. Structure 12 was designed from a previously 
investigated molecule 11, which had significant HERG affinity. Both structures 11 and 12 
contain a somewhat ubiquitous (privileged) piperidine motif which is also present in other 
structures under study, such as 9 and 10.  
 
Conclusion 
CCR5 antagonists remain an important class of drugs for HIV treatment. Their design has 
involved a balancing act, pitting desirable antiviral potency vs. undesirable HERG affinity. 
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An array of new generation antivirals are now being developed with even better properties 
e.g. oral bioavailability and longer onset of action. 
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